SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MisterED who wrote (2706)11/20/1997 10:33:00 PM
From: BigKNY3  Read Replies (1) of 23519
 
Mr ED <<On top of all that there seems to be less and less concern about competition from the pills which need one hour to work and last
ten minutes, has questionable systemic effects, and are many
months away, if not years>>

To date, I have not heard or read even one negative report about Viagra from patients or the Phase III investigators. The reported discontinuance rate of 2% due to side effects could be one of the lowest ever reported for a NDA submission.

Just yesterday, a Viagra investigator and a patient were featured on CBS This Morning. The 5 minute segment did not share any of your concerns about the commercial viability of Viagra but concluded "this revolutionary pill could soon be available to help millions of men."

Moreover, today a FDA Advisory Panel recommended approval of Lilly's Evista, a priority reviewed product. To date, no pending NDA that has completed a "priority track" by the FDA has failed to be recommended for approval by its FDA Panel.

BigKNY3
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News